menu
    • menu

    Company profile for Hemispherian

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.The Company’s lead compound is currently in late stage preclinical development for glioblastoma...
    Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients.The Company’s lead compound is currently in late stage preclinical development for glioblastoma multiforme, a deadly cancer of the central nervous system.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HemispherianNorway Flag
    Country
    Country
    Norway
    Address
    Address
    Lørenveien 73 0580 Oslo, Norway
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://hemispherian.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/hemispherian/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioLineRx, Hemispherian Dose First Patient in GBM Study
    BioLineRx, Hemispherian Dose First Patient in GBM Study

    28 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-first-patient-dosed-in-phase-12a-study-of-glix1-for-the-treatment-of-glioblastoma-gbm-302755515.html

    PR NEWSWIRE
    28 Apr 2026
    Share Share
    Hemispherian Initiates Phase 1/2a Trial of GLIX1 in Glioblastoma
    Hemispherian Initiates Phase 1/2a Trial of GLIX1 in Glioblastoma

    07 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260407249206/en/Hemispherian-Initiates-Phase-12a-Clinical-Trial-of-GLIX1-in-Glioblastoma

    BUSINESSWIRE
    07 Apr 2026
    Share Share
    Biolinerx Unveils Q3 2025 Financials And Corporate Update
    Biolinerx Unveils Q3 2025 Financials And Corporate Update

    24 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-reports-third-quarter-2025-financial-results-and-provides-corporate-update-302624413.html

    PR NEWSWIRE
    24 Nov 2025
    Share Share
    Hemispherian Secures GLIX1 Patent for Solid Tumors
    Hemispherian Secures GLIX1 Patent for Solid Tumors

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119133483/en/Hemispherian-Announces-USPTO-Notice-of-Allowance-for-Key-GLIX1-Patent-Covering-Majority-of-Solid-Tumors

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Biolinerx, Hemispherian As Form Joint Venture For Glix1
    Biolinerx, Hemispherian As Form Joint Venture For Glix1

    29 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biolinerx-ltd-and-hemispherian-as-establish-joint-venture-to-develop-glix1-a-first-in-class-oral-small-molecule-targeting-dna-damage-response-in-glioblastoma-and-other-cancers-302569321.html

    PR NEWSWIRE
    29 Sep 2025
    Share Share
    Hemispherian Gets FDA IND Clearance for Glioblastoma Drug GLIX1
    Hemispherian Gets FDA IND Clearance for Glioblastoma Drug GLIX1

    06 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hemispherian-receives-fda-ind-clearance-for-first-in-class-glioblastoma-therapeutic-glix1-302520810.html

    PR NEWSWIRE
    06 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search